| Literature DB >> 27222715 |
V Walewski1, F Méchaï2, T Billard-Pomares1, W Juguet3, F Jauréguy1, B Picard1, Y Tandjaoui-Lambiotte3, E Carbonnelle1, O Bouchaud2.
Abstract
Melioidosis is an endemic disease in Southeast Asia and northern Australia. An increasing number of cases are being reported in nonendemic countries, making the diagnosis less obvious. We discuss the identification of Burkholderia pseudomallei using matrix-assisted desorption ionization-time of flight mass spectrometry on the occasion of recent cases of imported melioidosis in French travellers.Entities:
Keywords: Burkholderia pseudomallei; MALDI-TOF MS; diagnosis; imported infectious disease; melioidosis
Year: 2016 PMID: 27222715 PMCID: PMC4872369 DOI: 10.1016/j.nmni.2016.04.004
Source DB: PubMed Journal: New Microbes New Infect ISSN: 2052-2975
Patient characteristics
| Patient No. | Gender (age, years) | Clinical presentation (date) | Visited country | Risk factor | Medical imaging | Laboratory results biology | Treatment (duration) | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | M (37) | Fever and mild cough, rapid evolution to acute respiratory distress, multiple organ failure (December 2013) | Thailand (Kho Phangan) | None; tattoo? | Chest x-ray revealed cavity-like lesion in upper lobe of right lung compatible with tuberculosis | Leukocytes: 22.4 × 109 L (81% neutrophils) HBV, HCV, HIV serologies: negative Malaria test: negative PCT: 0.98 μg/L | Amoxicillin (7 days) Amoxicillin-clavulanic acid (7 extra days) Piperacillin-tazobactam + amikacin Intravenous ceftazidime + cotrimoxazole (14 days) Maintenance oral cotrimoxazole (6 months) | After several weeks, acute renal failure persisted along with reduced respiratory capacity. |
| 2 | M (36) | Fever, chills, alteration of general state (April 2015) | Malaysia (Borneo) | None; flood? | Computed tomography chest scan revealed upper left lobe condensation | Leukocytes: 6.8 × 109 L (82% neutrophils) HBV, HCV, HIV serologies: negative Malaria test: negative PCT: 6.8 μg/L | Intravenous ceftazidime and oral cotrimoxazole (10 days) Maintenance oral cotrimoxazole (3 months) | Favorable clinical outcome was observed rapidly despite diagnosis of secondary prostatic abscess. To date, no relapse observed. |
| 3 | F (58) | Fever, chills, acute respiratory distress, diarrhoea, vomiting (August 2015) | Cambodia | Diabetes mellitus | Chest x-ray revealed alveolar condensation lesions in lower lobe of her left lung | Leukocytes: 19.6 G/L (88% neutrophils) HIV serology: negative PCT: 28.9 μg/L | Intravenous ceftriaxone for 24 hours; after bacterial identification, intravenous ceftazidime and oral cotrimoxazole (21 days) Maintenance oral amoxicillin–clavulanic acid (3 months) | Clinical course was rapidly favorable. Sepsis and urinary tract infection were observed 5 months after. |
HBV, hepatitis B virus; HCV, hepatitis C virus; PCT, procalcitonin.
Antimicrobial susceptibility (disk diffusion test) of three Burkholderia pseudomallei strains
| Strain | AMC | CAZ | IMP | TS | Gm | DX | CL |
|---|---|---|---|---|---|---|---|
| 1 | S | S | S | S | R | S | NT |
| 2 | S | S | S | S | S | S | NT |
| 3 | S | S | S | S | R | S | S |
AMC, amoxicillin–clavulanic acid; CAZ, ceftazidime; CL, chloramphenicol; DX, doxycycline; Gm, gentamicin; IMP, imipenem; NT, not tested; R, resistant; S, sensitive; TS, trimethoprim–sulfamethoxazole (cotrimoxazole).